不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>Mobidiag, Genewave与Amplidiag三公司合并

Mobidiag, Genewave与Amplidiag三公司合并

Mobidiag2013年4月16日 17:02 点击:1054

Mobidiag

Mobidiag4月12日表示,将与两家专门从事感染性疾病分子诊断公司联合,收购价格未公开。新Mobidiag将自己的多元专有诊断测试组合与Amplidiag公司的服务,以及Genewave公司的自动化和集成测试平台相结合。

  XINMobidiagJIANGYOUTuomas TenkanenDANRENCEO,Tuomas TenkanenSHIZHENDUANPCRCHANPINTIGONGZHEFinnzymesGONGSIDEQIANYANFAZHUGUAN,FinnzymesGONGSIYU2010NIAN3YUEBEIThermo FisherSHOUGOU。

  TONGGUOMobidiagGONGSIDEYONGYUXIAOHUADAOCHUANRANXINGJIBINGHEQITAYANZHONGJIBINGDEZHONGDUOZHUANLIJIANCEJISHUHEHESUANTIQUFANGFA,AmplidiagTIGONGGUANGFANDECHUANRANBINGZHENDUANCESHIFUWU。

不用本金就能赚钱的方法  GenewaveSHIYIJIACHUYUFAZHANQIDEZHENDUANGONGSI,ZHUANMENCONGSHIYONGYUZHENDUAN、LINCHUANGHEJICHUSHENGMINGKEXUEYANJIUDEWEIZHENLIEYIQIDEKAIFA、ZHIZAO、YINGXIAO。GAIGONGSIBIAOSHI,QIYIQICHANPINZHUYAOYONGYUKONGZHIYIYUANNEIGANRANCHUANBOHEKANGJUNZULI。

不用本金就能赚钱的方法  MobidiagZAIYIFENSHENGMINGZHONGBIAOSHI,ZHEIXIANGSHOUGOUJIANGSHITANENGGOUTIGONGZIDONGHUACESHI,JIEJUELINCHUANGSHIYANSHIYUDAODEYANZHONGCHUANRANSUOBINGXUYAODEZIDONGHUAJICHENGZHENDUANCESHI。

不用本金就能赚钱的方法  “ZHEISANGEHUBUDEGONGSIXIANGRONGHE,QITIGONGDEXIAYIDAICHUANRANBINGZHENDUANJISHUJIANGWEIXIANZHUGAISHANQUANQIUYILIAOBAOJIANCHUANGJIANYIGEDUTEDEJIHUI,”TenkanenZAIYIFENSHENGMINGZHONGSHUO。


 

Mobidiag, Genewave, and Amplidiag announce merger to create a leading innovator in molecular diagnostics

 

MERGER ANNOUNCEMENT
Helsinki, Finland and Paris, France  –  April 12, 2013

 

 

Mobidiag, Genewave, and Amplidiag announce merger to create a leading innovator in molecular diagnostics

 

- The new Mobidiag to offer integrated, high-multiplex diagnostic tests for infectious diseases

 

Mobidiag Oy/Ltd, Genewave SAS, and Amplidiag Oy today announced a definitive agreement to combine the three companies to create a technology leader in molecular diagnostics for infectious diseases. The new Mobidiag combines Mobidiag’s and Amplidiag’s high-multiplex proprietary diagnostic test portfolios with Genewave’s automated and integrated test platform. The merger was accompanied by a financing round by existing investors Helsinki University Fund, iXLife, Tutor Invest (Medtech Rahasto Ky), and others, as well as public funding support from the Finnish funding agencies, Tekes and Finnvera, and the EU. Joining as Mobidiag’s new CEO is Tuomas Tenkanen, the former R&D Director of the diagnostics PCR products provider, Finnzymes Oy, which was acquired by Thermo Fisher Scientific.

 

The transaction was effected as a share exchange, upon which Genewave and Amplidiag became subsidiaries of Mobidiag Oy/Ltd. The new company is headquartered in Helsinki, with a center of excellence in Paris, and now has the diagnostic test pipeline, integrated test platform, leadership, infrastructure, and financial resources to develop and bring to commercialization its automated instrument and panel of diagnostic tests, capable of identifying a large number of pathogens from a single patient sample.

 

“The fusion of these three complementary companies creates a unique opportunity to bring forward the next generation of infectious disease diagnostics to dramatically improve global health care,” said Tuomas Tenkanen, CEO, Mobidiag.

 

Genewave specializes in the development, manufacturing and marketing of cutting-edge microarray instrumentation for diagnostic, clinical and life science research. Genewave’s innovative GeneSpress® system is an automated and integrated platform for highly multiplexed molecular diagnostic tests. The compact system integrates DNA purification, PCR amplification and microarray hybridization and detection into an automated workflow on a single, closed lab-on-chip cartridge. Among other innovative features, the platform incorporates Genewave’s patented TouchArray™ optical detection technology for highly sensitive imaging of microarrays.

 

Mobidiag’s clinically proven, CE-IVD marked Prove-it™ diagnostic tests enable up to 84 pathogens and antibiotic resistance markers to be detected in a single assay, representing cutting-edge multiplexing capabilities. Current test products are intended for diagnosing bacterial and fungal sepsis, viral central nervous system infections and bacterial bone and joint infections. Mobidiag has built a reference customer base with its current test portfolio and has generated market acceptance in Europe. The automation of Mobidiag’s tests will answer the need of clinical laboratories for automated and integrated solutions for diagnostic testing of severe infectious diseases.

 

Amplidiag provides a broad panel of diagnostic tests for infectious diseases. Amplidiag has substantial intellectual property covering testing and nucleic acid extraction methods for contagious gastrointestinal and other serious diseases.

 

The global molecular diagnostics market exceeds 5 billion EUR, and is growing more than 15% annually.

 

 

 

For further information on the companies, please visit  and.

 

 

Contact:
Mobidiag Oy/Ltd.
Tuomas Tenkanen, CEO
+350 50 553 4980
tuomas.tenkanen@mobidiag.com

 

Tuomas Tenkanen, the newly appointed CEO of Mobidiag, with a prototype of the GeneSpress® system.

 

 

Read the press release as a pdf version .

(来源: Mobidiag )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com不用本金就能赚钱的方法

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图